Amylyx Pharmaceuticals (AMLX) Other Non-Current Assets (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Other Non-Current Assets of $2.5 million for Q1 2026, up 22627.27% year-over-year from N/an in Q1 2025, and up 153.81% quarter-over-quarter from $985000.0 in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $2.5 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 22627.27% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (up 22627.27% YoY), while the FY2025 annual figure was $985000.0, up 4004.17% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $2.5 million, up from $985000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $2.5 million in Q3 2025, with the low at $11000.0 in Q1 2025.
- The 5-year median for Other Non-Current Assets is $493000.0 (2024), against an average of $838705.9.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets sank 97.77% in 2025, then surged 22627.27% in 2026.
- Amylyx Pharmaceuticals' Other Non-Current Assets stood at $700000.0 in 2022, then rose by 0.14% to $701000.0 in 2023, then slumped by 96.58% to $24000.0 in 2024, then soared by 4004.17% to $985000.0 in 2025, then jumped by 153.81% to $2.5 million in 2026.
- Business Quant data shows AMLX's Other Non-Current Assets at $2.5 million in Q1 2026, $985000.0 in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 13.00 Mn |
| 10 | Amylyx Pharmaceuticals | 4.34 Bn | 4.34 Bn | - | 2.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.50 Mn |
| Mar 31, 2026 | 2.50 Mn |
| Dec 31, 2025 | 985,000.00 |
| Sep 30, 2025 | 2.50 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Mar 31, 2025 | 11,000.00 |
| Dec 31, 2024 | 24,000.00 |
| Sep 30, 2024 | 1.44 Mn |
| Jun 30, 2024 | 479,000.00 |
| Mar 31, 2024 | 493,000.00 |
| Dec 31, 2023 | 701,000.00 |
| Sep 30, 2023 | 476,000.00 |
| Jun 30, 2023 | 466,000.00 |
| Mar 31, 2023 | 719,000.00 |
| Dec 31, 2022 | 700,000.00 |
| Sep 30, 2022 | 456,000.00 |
| Jun 30, 2022 | 456,000.00 |
| Mar 31, 2022 | 400,000.00 |
| Dec 31, 2021 | 189,000.00 |